Medical Oncology

Uzm. Dr. Abdussamet Çelebi

Doctor and researcher Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi İstanbul
Breast NeoplasmsColonic NeoplasmsLung NeoplasmsBrain NeoplasmsCarcinoma, Non-Small-Cell LungAdenocarcinomaLiver NeoplasmsBiliary Tract NeoplasmsBreast Neoplasms, MaleCarcinoma, Renal CellKidney NeoplasmsSarcomaSoft Tissue Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 6 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Colonic Neoplasms 5 publications
  • Lung Neoplasms 4 publications
  • Brain Neoplasms 3 publications
  • Carcinoma, Non-Small-Cell Lung 3 publications
  • Adenocarcinoma 2 publications
  • Liver Neoplasms 2 publications
  • Biliary Tract Neoplasms 2 publications
  • Breast Neoplasms, Male 2 publications
  • Carcinoma, Renal Cell 2 publications
  • Kidney Neoplasms 2 publications
  • Sarcoma 2 publications
  • Soft Tissue Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionMarmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 6 publications · Model version —From source
  • Publications63 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-6922-1018ORCIDFrom source
  • Last synchronised5 November 2026 10:37https://marmaraeah.saglik.gov.tr/TR-1393453/doktorlarimiz.html#abdussamet-celebisaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

63 publications

  1. Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000604 PMID 41972337 Source: OpenAlex

  2. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Open-access full textSource: OpenAlex

  3. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Source: OpenAlex

  4. Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach

    Brain Sciences, 2026

    DOI 10.3390/brainsci16010097 PMID 41594818 Open-access full textSource: ORCID

  5. Kanser Hastalarının Bakım Verenlerinin Bakım Yükü: Manevi İyilik Hali, Psikolojik Esneklik, Depresyon ve Anksiyete Arasındaki İlişki-Ön Bulgular

    Turkish Journal of Psychiatry, 2026

    DOI 10.5080/61upk.ozt269 Open-access full textSource: OpenAlex

  6. Acquired CD74–ROS1 fusion–mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report

    Journal of Chemotherapy, 2026

    DOI 10.1080/1120009x.2026.2657116 PMID 41992733 2 citations (OpenAlex) Source: OpenAlex

  7. Digital health engagement and health literacy among cancer patients: a cross-sectional study of ICT usage patterns

    BMC Health Services Research, 2026

    DOI 10.1186/s12913-026-15432-y 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  8. Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study

    Journal of Neuro-Oncology, 2026

    DOI 10.1007/s11060-025-05415-0 PMID 41492105 Source: OpenAlex

  9. Oncological Perspective on Bone-Metastatic Colorectal Cancer: a Single-Centre Experience

    Journal of Gastrointestinal Cancer, 2026

    DOI 10.1007/s12029-026-01457-3 PMID 41944932 Source: OpenAlex

  10. Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15176790 PMID 42739793 Open-access full textSource: OpenAlex

View all 63 publications